What is First Tracks Biotherapeutics Inc's D&A?

First Tracks Biotherapeutics Inc (TRAX) reported D&A of $125K in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

First Tracks Biotherapeutics Inc (TRAX) D&A

Screener

D&A at other companies

BKBK

$415M-7.0%

GPA

General Purpose Acquisition Corp.GPAC

$992+29.8%

Schering-PloughSGP

$153K+126%

Dycom IndustriesDY

$111.64M+91.2%

Dollar GeneralDG

$270.83M+7.1%

TargetTGT

$685M+4.6%

Where this comes from

Reported directly by First Tracks Biotherapeutics Inc in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026. Open the filing →

Filed: May 14, 2026, 4:32 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001193125-26-224190

FAQ

What is First Tracks Biotherapeutics Inc's D&A?: First Tracks Biotherapeutics Inc (TRAX) reported D&A of $125K in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about First Tracks Biotherapeutics Inc's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

First Tracks Biotherapeutics Inc TRAX D&A

D&A at other companies

Where this comes from

FAQ

Ask your AI about First Tracks Biotherapeutics Inc's d&a.